|
1
|
Hensing T, Chawla A, Batra R and Salgia R:
A personalized treatment for lung cancer: molecular pathways,
targeted therapies, and genomic characterization. Adv Exp Med Biol.
799:85–117. 2014.
|
|
2
|
Kaneda H, Yoshida T and Okamoto I:
Molecularly targeted approaches herald a new era of non-small-cell
lung cancer treatment. Cancer Manag Res. 5:91–101. 2013.
|
|
3
|
Gainor JF, Varghese AM, Ou SH, et al: ALK
rearrangements are mutually exclusive with mutations in EGFR or
KRAS: an analysis of 1,683 patients with non-small cell lung
cancer. Clin Cancer Res. 19:4273–4281. 2013.
|
|
4
|
Kuo YW, Wu SG, Ho CC and Shih JY: Good
response to gefitinib in lung adenocarcinoma harboring coexisting
EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol.
5:2039–2040. 2010.
|
|
5
|
Popat S, Vieira de Araújo A, Min T, et al:
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK
rearrangement responding to erlotinib. J Thorac Oncol. 6:1962–1963.
2011.
|
|
6
|
Miyanaga A, Shimizu K, Noro R, et al:
Activity of EGFR-tyrosine kinase and ALK inhibitors for
EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting
EGFR mutation. BMC Cancer. 13:2622013.
|
|
7
|
Tanaka H, Hayashi A, Morimoto T, et al: A
case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK
fusion gene. BMC Cancer. 12:5582012.
|
|
8
|
Toyokawa G, Taguchi K, Ohba T, et al:
First case of combined small-cell lung cancer with adenocarcinoma
harboring EML4-ALK fusion and an exon 19 EGFR mutation in each
histological component. J Thorac Oncol. 7:e39–e41. 2012.
|
|
9
|
Sasaki T, Koivunen J, Ogino A, et al: A
novel ALK secondary mutation and EGFR signaling cause resistance to
ALK kinase inhibitors. Cancer Res. 71:6051–6060. 2011.
|
|
10
|
Rodríguez PC, Rodríguez G, González G and
Lage A: Clinical development and perspectives of CIMAvax EGF, Cuban
vaccine for non-small-cell lung cancer therapy. MEDICC Rev.
12:17–23. 2010.
|
|
11
|
National Cancer Institute (NCI). Common
Terminology Criteria for Adverse Events (CTCAE), version 4.03. June
14–2010
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
|
|
13
|
Oxnard GR, Arcila ME, Chmielecki J,
Ladanyi M, Miller VA and Pao W: New strategies in overcoming
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in lung cancer. Clin Cancer Res. 17:5530–5537.
2011.
|
|
14
|
Lee JC, Jang SH, Lee KY and Kim YC:
Treatment of non-small cell lung carcinoma after failure of
epidermal growth factor receptor tyrosine kinase inhibitor. Cancer
Res Treat. 45:79–85. 2013.
|
|
15
|
Shimizu K, Yukawa T, Hirami Y, et al:
Heterogeneity of the EGFR mutation status between the primary tumor
and metastatic lymph node and the sensitivity to EGFR tyrosine
kinase inhibitor in non-small cell lung cancer. Target Oncol.
8:237–242. 2013.
|
|
16
|
Bai H, Wang Z, Chen K, et al: Influence of
chemotherapy on EGFR mutation status among patients with
non-small-cell lung cancer. J Clin Oncol. 30:3077–3083. 2012.
|
|
17
|
Kim S, Kim TM, Kim DW, et al:
Heterogeneity of genetic changes associated with acquired
crizotinib resistance in ALK-rearranged lung cancer. J Thorac
Oncol. 8:415–422. 2013.
|
|
18
|
Ji W, Choi CM, Rho JK, et al: Mechanisms
of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean
patients with lung cancer. BMC Cancer. 13:6062013.
|
|
19
|
Murtaza M, Dawson SJ, Tsui DW, et al:
Non-invasive analysis of acquired resistance to cancer therapy by
sequencing of plasma DNA. Nature. 497:108–112. 2013.
|
